InsidersTradesSigma
Novonesis (Novozymes A/S) Stock: price and management transactions · Denmark · Finanstilsynet DK
Follow the Novonesis (Novozymes A/S) share price and the full directors' dealings record of the company, a listed equity based in Denmark. Shares are listed on DK DK, under the authority of Finanstilsynet DK. Operating in the Chemicals sector, Novonesis (Novozymes A/S) has logged 28 reports. Market capitalisation: €172.5bn. The latest transaction was filed on 11 November 2021 (Purchase). Among the most active insiders: Unknown. The full history is accessible without an account.
28
Insider Decl.
0
Thresholds
·
15 ops.
Buy Volume
·
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Novonesis (Novozymes A/S) Buy (bullish), based on 17 analysts. Average price target: DKK 461.41.
32Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 13,554 of 26,179 companies
50.9
score / 100
Value37
Quality65
FCF yld0.4%
Earn yld0.3%
EV/EBITDA·
ROE5.4%
Gross mgn54%
Net mgn14%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 11 November 2021
Declarations28 total
ShareDK:1124431
Ideal exit: 7 Aug 2022 (T+270)
ShareDK:1122183
Ideal exit: 25 Jul 2022 (T+270)
ShareDK:1122075
Ideal exit: 25 Jul 2022 (T+270)
ShareDK:1005046
Ideal exit: 14 Nov 2021 (T+270)
ShareDK:1004383
Ideal exit: 9 Nov 2021 (T+270)
ShareDK:1003359
Ideal exit: 31 Oct 2021 (T+270)
ShareDK:1003185
Ideal exit: 31 Oct 2021 (T+270)
ShareDK:960384
Ideal exit: 24 Jul 2021 (T+270)
ShareDK:959514
ShareDK:954573
Ideal exit: 5 Jun 2021 (T+270)
ShareDK:954345
Ideal exit: 1 Jun 2021 (T+270)
ShareDK:954208
Ideal exit: 29 May 2021 (T+270)
ShareDK:953995
Ideal exit: 30 May 2021 (T+270)
●
Unknown
The CEO of Novo Holdings A/S serves on the Board of Directors of Novozymes A/S, andExecutives
32DK FSA ↗
765,000 shares@ €102,719.614545.55% mcap100.0% of flowShareDK:951615
ShareDK:942216
Ideal exit: 20 Feb 2021 (T+270)
ShareDK:941755
Ideal exit: 14 Feb 2021 (T+270)
●
Unknown
The CEO of Novo Holdings A/S serves on the Board of Directors of Novozymes A/S, andExecutives
ShareDK:938127
ShareDK:937832
Ideal exit: 25 Jan 2021 (T+270)
ShareDK:686564
ShareDK:682439
ShareDK:645580
ShareDK:625185
ShareDK:612754
ShareDK:611820
ShareDK:606890
25 of 28 declarations
About Novonesis (Novozymes A/S)
Novonesis is a biotechnology company focused on developing enzymatic solutions for various sectors. It is part of Novozymes A/S, a global leader in enzymes and microorganisms.